-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018..
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).. she suffered a "third brain bleed" and was pronounced brain dead on monday..